Insulin sensitivity and early-phase insulin secretion in normoglycemic huntington’s disease patients

Journal of Huntington's Disease

Volumn 2, Issue 4, 2013, Pages 501-507

  Russo, Cinzia V ^a   Salvatore, Elena ^a   Tucci, Tecla ^a   Rinaldi, Carlo ^a   Sorrentino, Pierpaolo ^a   Massarelli, Marco ^a   Rossi, Fabiana ^a   Savastano, Silvia ^a   Di Maio, Luigi ^a   Filla, Alessandro ^a   Colao, Annamaria ^a   De Michele, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Glucose regulation; Huntington s disease; Insulin secretion; Insulin sensitivity

Indexed keywords

ADULT; ARTICLE; BLOOD; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE REGULATION; GLUCOSE TOLERANCE TEST; HUMAN; HUNTINGTON CHOREA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MIDDLE AGED; PHYSIOLOGY;

GLUCOSE REGULATION; HUNTINGTON'S DISEASE; INSULIN SECRETION; INSULIN SENSITIVITY;

ADULT; BLOOD GLUCOSE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HUNTINGTON DISEASE; INSULIN RESISTANCE; MALE; MIDDLE AGED;

EID: 84906924911     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-130078     Document Type: Article

References (42)

1. Walker FO. Huntington’s disease. Lancet. 2007;369(9557):218-28.
2. Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971-83.
3. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, LoA, Hedreen J, Sisodia S, Snyder SM, Dawson TM, Ryugo DK, Ross CA. Widespread expression of Huntington disease’s gene (IT15) protein product. Neuron. 1995;14(5):1065-74.
4. Ross CA, Tabrizi SJ. Huntington’s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98.
5. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci. 2005;25(4):157-63.
6. Aziz NA, Pijl H, Froelich M, van der Graaf AW, Roelfsema F, Roos RA. Increased hypothalamic-pituitary-adrenal axis activity in Huntington’s disease. J Clin Endocrinol Metab. 2009;94(4):1223-8.
7. Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, Broussolle E, Morin F, Bachoud-Lévi AC, Maison P. Neuroendocrine disturbances in Huntington’s disease. PLoS One. 2009;4(3):e4962.
8. Hult S, Schultz K, Soylu R, Petersén A. Hypothalamic and neuroendocrine changes in Huntington’s disease. Curr Drug Targets. 2010;11(10):1237-49.
9. Salvatore E, Rinaldi C, Tucci T, Di Maio L, Di Somma C, Savastano S, Lombardi G, Filla A, Colao A, De Michele G. Growth hormone response to arginine test differentiates between two subgroups of Huntington’s disease patients. J Neurol Neurosurg Psychiatry. 2011;82(5):543-7.
10. Cohen E, Dillin A. The insulin paradox: Aging, proteotoxicity and neurodegeneration. Nat Rev Neurosci. 2008;9(10):759-67.
11. Hurlbert MS, Zhou W, Wasmeier, Kaddis FG, Hutton JC, Freed CR. Mice transgenic for an expanded CAG repeat in the Huntington’s disease gene develop diabetes. Diabetes. 1999;48(3):649-51.
12. Smith R, Bacos K, Fedele V, Soulet D, Walz HA, Obermüller S, Lindqvist A, Björkqvist M, Klein P, Onnerfjord P, Brundin P, Mulder H, Li JY. Mutant huntingtin interacts with betatubulin and disrupts vesicular transport and insulin secretion. Hum Mol Genet. 2009;18(20):3942-54.
13. Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington’s disease. PLoS One. 2009;4(11):e8025.
14. Boesgaard TW, Nielsen TT, Josefsen K, Hansen T, Jørgensen T, Pedersen O, Nørremølle A, Nielsen JE, Hasholt L. Huntington’s disease does not appear to increase the risk of diabetes mellitus. J Neuroendocrinol. 2009;21(9):770-6.
15. Huntington Study Group. Unified Huntington’s disease rating scale: Reliability and consistency. Mov Disord. 1996;11(2):136-42.
16. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, Lombardi G, Savastano S. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: An observational, exploratory study in 404 subjects. Eur J Endocrinol. 2008;159(4):389-97.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64-71.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia. 1985;28(7):412-9.
19. Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol. 2004;150(2):97-104.
20. Monesi L, Baviera M, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Cortesi L, Riva E, Fortino I, Bortolotti A, Fontana G, Merlino L, Roncaglioni MC. Prevalence, incidence and mortality of diagnosed diabetes: Evidence from an Italian population-based study. Diabet Med. 2012;29(3):385-92.
21. Bacos K, Björkqvist M, Petersén A, Luts L, Maat-Schieman ML, Roos RA, Sundler F, Brundin P, Mulder H, Wierup N. Islet beta-cell area and hormone expression are unaltered in Huntington’s disease. Histochem Cell Biol. 2008;129(5):623-9.
22. Podolsky S, LeopoldNA, Sax DS. Increased frequency of diabetes mellitus in patients with Huntington’s chorea. Lancet. 1972;1(7765):1356-8.
23. Davidson MB, Green S, Menkes JH. Normal glucose, insulin and growth hormone responses to oral glucose in Huntington’s disease. J Lab Clin Med 1974;84:807-12.
24. Schubotz R, Hausmann L, Kaffarnik H, Zehner J, Oepen H. Fatty acid patterns and glucose tolerance in Huntington’s chorea. Res Exp Med. 1976;167(3):203-15.
25. Phillipson OT, Bird ED. Plasma glucose, non-esterified fatty acids and aminoacids in Huntington’s chorea. Clin Sci Mol Med. 1977;52(3):311-8.
26. Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet. 1985;27(1):62-7.
27. Kremer HP, Roos RA, Frölich M, Radder JK, Nieuwenhuijzen Kruseman AC, Van der Velde A, Buruma OJ. Endocrine functions in Huntington’s disease. A two and a half years follow-up study. J Neurol Sci. 1989;90(3):335-44.
28. Lalić NM, Marić J, Svetel M, Jotić A, Stefanova E, Lalić K, Dragasević N, Milicić T, Lukić L, Kostić VS. Glucose homeostasis in Huntington disease: Abnormalities in insulin sensitivity and early phase insulin secrection. Arch Neurol. 2008;65(4):476-80.
29. van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates GP, Brundin P, Björkqvist M, Wierup N. Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol Dis. 2011;44(1):1-8.
30. Aziz NA, Anguelova GV, Marinus J, van Dijk JG, Roos RA. Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington’s disease. Eur J Neurol. 2010;17(8):1068-74.
31. Kobal J, Melik Z, Cankar K, Bajrovic FF, Meglic B, Peterlin B, Zaletel M. Autonomic dysfunction in presymptomatic and early symptomatic Huntington’s disease. Acta Neurol Scand. 2010;121(6):392-99.
32. Godsland IF, Crook D, Walton C, Wynn V, Oliver MF. Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men. Arterioscler Thromb. 1992;12(9):1030-5.
33. Laakso M, Sarlund H, Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance Arteriosclerosis. 1990;10(2):223-31.
34. Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson, I. Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol. 2010;4(1):17-23.
35. Leoni V, Mariotti C, Nanetti L, Salvatore E, Squitieri F, Bentivoglio AR, Bandettini di Poggio M, Piacentini S, Monza D, Valenza M, Cattaneo E, Di Donato S. Whole body cholesterol metabolism is impaired in Huntington’s disease. Neurosci Lett. 2011;494(3):245-9.
36. Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, Broussolle E, Morin F, Bachoud-Lévi AC, Maison P. Neuroendocrine disturbances in Huntington’s disease. PLoS One. 2009;4(3):e4962.
37. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A. Early energy deficit in Huntington disease: Identification of a plasma biomarker traceable during disease progression. PLoS One. 2007;2(7):e647.
38. Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, Miljic D, Milic N, Glodic J, Dieguez C, Casanueva FF, Kostic V. Circulating and cerebrospinal fluid ghrelin and leptin: Potential role in altered body weight in Huntington’s disease. Eur J Endocrinol. 2004;151(4):451-5.
39. Aziz NA, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, Roos RA. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington’s disease. Eur J Neurol. 2010;17(2): 280-8.
40. Humbert S, Bryson EA, Cordeli`eres FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington’s disease and involves Huntingtin phosphorylation by Akt. Dev Cell. 2002;2(6):831-7.
41. Duarte AI, Petit GH, Ranganathan S, Li JY, Oliveira CR, Brundin P, Björkqvist M, Rego AC. IGF-1 protects against diabetic features in an in vivo model of Huntington’s disease. Exp Neurol. 2011;231(2):314-9.
42. Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, EI Hawajri N, Bachoud-Lévi AC, Maison P; Huntington French Speaking Group. High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology. 2010;75(1):57-63.